The S.L.E. Lupus Foundation is advocating for wider access to medication for patients who suffer from systemic lupus erythematosus (SLE) by signing two Memorandums of Support for Legislative Acts. The non-profit organization, which works as part of the Lupus Agencies of New York State, believes that the memorandums can help…
Researchers at the Yale Cancer Center and the Veterans Affairs Greater Los Angeles Healthcare System, recently presented a new method to re-engineer lupus autoantibodies and transform them into potential cancer killers during the American Association for Cancer Research Annual Meeting 2015, Philadelphia. Systemic lupus erythematosus (SLE) is a…
The Lupus Foundation of America is hosting another edition of its Walk to End Lupus Now, an annual event that takes place across the country to support the fight against lupus, which is scheduled for Saturday, May 2. Last year the walk was the largest LFA-sponsored walk in the nation, gathering…
The non-profit organization Lupus Foundation of America continues the fight against lupus by supporting research projects seeking to discover and develop an effective treatment or a cure for the chronic disease. To do so, the foundation trusts in the contribution of numerous volunteers and donators and is now sharing the…
Actelion recently announced its commitment to accelerate clinical development efforts concerning immunological disorders following a broad medical, scientific and commercial assessment of a series of its selective S1P1 receptor modulators, discovered in-house. The company believes that this effort will lead to new approaches addressing systemic lupus erythematosus. A second selective S1P1 receptor modulator will be…
Patients with systemic lupus erythematosus (SLE) display a wide range of symptoms and disease activity. Accordingly, there are a variety of therapeutic regimens designed for them. Each has its own mechanism of action, but often times patients experience the same clinical relief of symptoms. This can confound the clear choice…
A research team has recently showed that the natural product astilbin can diminish disease development in mice susceptible to lupus by decreasing functional activated T and B cells. The study entitled “Decrease of Functional Activated T and B Cells and Treatment of Glomerulonephitis in Lupus-Prone Mice Using a Natural Flavonoid…
Paris, France based Neovacs, a biotech firm specializing in active immunotherapies for treating autoimmune diseases, has announced establishment of a wholly-owned U.S. subsidiary, Neovacs, Inc., which is headquartered in Boston and incorporated in Delaware. Creation of a U.S. subsidiary is an important strategic step for Neovacs in extending clinical initiatives…
This year’s edition of the New York Lupus Handbag Luncheon gathered over 350 people in a fundraising effort to help support research on the chronic disease lupus last Monday, April 13. The event, which is organized annually by both the S.L.E. Lupus Foundation and the Lupus Research Institute (LRI), included prominent…
Several research teams at the New York University School of Medicine – Langone Medical Center recently presented their latest discoveries on key clinical aspects of Systemic Lupus Erythematosus at the NYU Seminar in Advanced Rheumatology. In a study entitled Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH)…